Lenvervimab
Based on 1 Customer Validation
Lenvervimab (GC1102) is a IgG1-type recombinant human hepatitis B Immunoglobulin. Lenvervimab can be used for research of hepatitis B virus infection.
For research use only. We do not sell to patients.
- Purity: ≥99%
- CAS No.: 2055006-79-4
- Molecular Weight:147.526 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Human IgG1 kappa
Virus
HBV
Lenvervimab (1 nM-1 μM, 16 h) inhibits HBV infection in HepG2-NTCP cells infected with HBV[1].
Lenvervimab recognizes many viral genotypes and clinical variants of HBV infection[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HepG2-NTCP cells infected with HBV
-
Concentration:1 nM-1 μM
-
Incubation Time:16 h
-
Result:Inhibited viral expression of the surface antigen HBsAg (hepatitis B virus surface antigen) and the core protein HBcAg.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
Chemical Information
-
CAS No. 2055006-79-4
-
Appearance Liquid
-
Molecular Weight 147.526 kDa
-
Color Colorless to light yellow
-
SMILES
[Lenvervimab]
-
Synonyms
GC1102
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (257 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Jeong GU, et al. A recombinant human immunoglobulin with coherent avidity to hepatitis B virus surface antigens of various viral genotypes and clinical mutants. PLoS One. 2020 Aug 13;15(8):e0236704. [Content Brief]
[2]. Lee HW, et al. Efficacy of Lenvervimab, a Recombinant Human Immunoglobulin, in Treatment of Chronic Hepatitis B Virus Infection. Clin Gastroenterol Hepatol. 2020 Dec;18(13):3043-3045.e1. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz